Welcome to our dedicated page for CHARLES RIVER LABORATORIES INTERNATIONAL SEC filings (Ticker: CRL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CHARLES RIVER LABORATORIES INTERNATIONAL's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CHARLES RIVER LABORATORIES INTERNATIONAL's regulatory disclosures and financial reporting.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) director James C. Foster reported an option exercise-and-sale transaction in the company’s common stock. On August 25, 2026, he exercised stock options covering 33,561 shares of common stock at exercise prices of $194.12 and $208.44 per share, receiving the underlying shares.
On the same date, he sold 33,561 shares of common stock at $300.00 per share in an open market or private transaction. According to the filing, this exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan initially adopted on March 6, 2026. Following these transactions, Foster also reports indirect holdings of common stock through several trusts and Grantor Retained Annuity Trusts.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) is the issuer for a planned resale of its common stock under Rule 144 by director James Foster. The notice covers 33,561 shares of common stock, with an aggregate market value of $10,065,950.73, relative to 47,738,872 shares outstanding as of August 25, 2026.
The shares are to be sold through UBS Financial Services, Inc. on the NYSE, in connection with an exercise of stock options for cash on August 25, 2026. Foster also reported prior sales in the past three months totaling 103,733 shares for combined proceeds of $24,776,575.00.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported an insider equity transfer by Chief Executive Officer and director Birgit Girshick. On 2026-08-19, Girshick made a bona fide gift of 528 shares of Common Stock, leaving 35,485 shares held directly and 43,803 shares held indirectly through a revocable trust.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) executive Shannon M. Parisotto, CEVP, Discovery & Safety Assessment, reported an option exercise-and-sale transaction. Parisotto exercised 2,039 stock options at an exercise price of $194.12 per share, acquiring 2,039 common shares, and then sold 2,039 common shares at $294.12 per share. The sale was made pursuant to a Rule 10b5-1 Trading Plan initially adopted on March 4, 2026. Following these transactions, Parisotto reports indirect ownership of 9,680 common shares by a trust and 28,510 common shares through Karpathos Investments LLC, as shown in the holding entries.
For CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL), director Nancy C. Andrews reported an option exercise and same-day sale. She exercised 573 stock options at an exercise price of $164.30 per share, acquiring 573 shares of common stock, and then sold 573 common shares at $285.24 per share. After these transactions, she reported 3,964 common shares held indirectly by trust. The Rule 10b5-1 trading-plan box was not checked.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) is the issuer of common stock that an officer, Shannon M. Parisotto, has notified for potential resale under Rule 144. The notice lists 2,039 common securities, with UBS Financial Services Inc. acting as broker, and references the NYSE and a date of 08/19/2026.
The filing also lists prior dispositions of CRL common securities by Shannon M. Parisotto during the past three months: 5,046 units on 08/05/2026 and 3,714 units on 08/11/2026, each with stated transaction values. A figure of 47,738,872 common securities is shown for CRL, providing context for the issuer’s total amount of this class.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) is the issuer for which a holder, Nancy C. Andrews, has filed a notice of proposed sale under Rule 144. The notice covers the potential sale of 573 shares of common stock, with an aggregate market value of 163,305, out of 48,167,730 shares outstanding, through UBS Financial Services Inc., with an approximate sale date of 08/18/2026 following a stock option exercise.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Chief Executive Officer Birgit Girshick exercised stock options for 6,500 shares of common stock on August 11, 2026 at an exercise price of $179.66 per share. The resulting 6,500 common shares were then sold at $279.90 per share on the same date, in a transaction marked as a sale. The company reports that this exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan initially adopted on March 3, 2025. Following these transactions, Girshick has an indirect holding of 43,803 common shares through a revocable trust.
Charles River Laboratories International executive Shannon M. Parisotto, CEVP, Discovery & Safety Assessment, exercised stock options for 3,714 shares of common stock at an exercise price of $179.66 per share on 2026-08-11 and sold the same 3,714 shares at $279.66 per share. The exercise and sale were carried out pursuant to a Rule 10b5-1 Trading Plan initially adopted on March 4, 2026. Following these transactions, reported indirect holdings include 9,680 shares held by a trust and 28,510 shares held by Karpathos Investments LLC.
Invesco Ltd., a Bermuda-based parent holding company, reports a significant passive ownership position in Charles River Laboratories International, Inc. common stock. Invesco may be deemed to beneficially own 2,984,785 shares, representing 6.2% of the outstanding common stock, held of record by its investment advisory clients.
Invesco has sole voting power over 2,955,113 shares and sole dispositive power over 2,984,785 shares, with no shared voting or dispositive power. The filing notes that no single underlying client has more than 5% economic ownership of Charles River’s common stock; the relevant clients receive dividends and sale proceeds. Subsidiaries involved include Invesco Advisers, Inc., Invesco Asset Management Limited, and Invesco Capital Management LLC.